Abstracts tagged "Antibodies"

Abstract Number: 1936 • 2012 ACR/ARHP Annual Meeting
The Human Leukocyte Antigen DRB1*13:02-DQB1*06:04-DPB1*04:01 Haplotype Is Closely Associated with Dermatomyositis Patients with Anti-CADM-140 (Melanoma Differentiation-Associated Protein 5: MDA5) Antibody
Yuji Hosono¹, Chikashi Terao², Ran Nakashima¹, Yoshitaka Imura³, Naoichiro Yukawa⁴, Hajime Yoshifuji¹, Motomu Hashimoto⁵, Koichiro Ohmura⁶, Takao Fujii⁷ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Dept of Rheum & Clinical Immun, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Rheumatology & Clin Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁷Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Recent studies have revealed that anti-CADM-140 (MDA5/IFIH1)-antibody positive dermatomyositis (DM) patients frequently develop acute or subacute progressive interstitial pneumonia (A/SIP) with poor prognosis. However,…
Abstract Number: 1748 • 2012 ACR/ARHP Annual Meeting
Antibody Secreting Cells Arising After Vaccination of Lupus Patients May Produce High Affinity Autoantibodies
Kenneth Smith¹, Jennifer Muther¹, Angie Duke¹, Emily McKee¹, Alina Lorant¹, Patrick C. Wilson² and Judith A. James³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Rheumatology and Knapp center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Vaccinating SLE patients with influenza and pneumococcal vaccines is generally considered safe and effective. However, conflicting reports regarding the impact of vaccination on autoantibody…
Abstract Number: 1491 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis – Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A On Effector Cells
Jeannine Guenther¹, Angela Kill², Mike O. Becker³ and Gabriela Riemekasten⁴, ¹Rheumatology/Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, Berlin, Germany, ²Rheumatology and clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany
Background/Purpose: Autoimmunity, vasculopathy and fibrosis are features of systemic sclerosis (SSc). The functional link between these three pathophysiological components is still missing. Research suggests an…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].